Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, Affymetrix, Qiagen, Beckton Dickinson, Agilent, BioMicro Systems


Sequenom this week launched iPlex, a new multiplexing SNP-genotyping assay that is compatible with the company's PCR-based MassArray System platform for genetic analysis.

The San Diego-based company said that iPlex is aimed at reducing cost, time, and yield for limited SNP sets, and would be useful for clinical research and microarray data validation.

Affymetrix last week launched its new GeneChip Globin-Reduction Kits and associated reagents.

The new kits were developed with PreAnalytiX — a joint venture between Qiagen and Beckton Dickinson — and use the PreAnalytiX PAXgene Blood RNA System to improve gene expression profile results of cellular RNA extracted from whole blood.

The kits and reagents allow researchers to reduce globin messenger RNA, which often interferes with gene expression associated with white blood cells and increases assay sensitivity.

Agilent last week rolled out its Laboratory Resource Management (LRM) service for life science and pharmaceutical laboratories.

The Palo Alto, Calif.-based company will now place its technical engineers on site to handle maintenance, repair, regulatory compliance, and workflow consulting.

The company claims the goal of LRM is to increase user productivity and reduce instrument downtime.

BioMicro Systems last week launched its MAUI 12-Bay Hybridization System, the company said.

The MAUI 12-Bay System is designed to meet the high-throughput needs of microarray labs and can process 12 microarray slides at once, achieve an increase in sensitivity with low-sample volumes, and cut time off the hybridization process, BioMicro Systems claimed.

The system is the latest addition to the company's MAUI product line that includes the MAUI 4-Bay Hybridization System and its line of MAUI Mixer hybridization chambers.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.